Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Evaluation of MPA and MPAG Removal by Continuous Venovenous Hemodiafiltration and Continuous Venovenous Hemofiltration

Cussonneau, Xavier PharmD*; Bolon-Larger, Magali PhD*†; Prunet-Spano, Céline PhD*; Bastien, Olivier PhD; Boulieu, Roselyne PhD*†

doi: 10.1097/FTD.0b013e3181633667
Short Communication
Buy

Abstract: The study assessed the removal of mycophenolic acid (MPA) and its major glucuronide metabolite (MPAG) during continuous venovenous hemofiltration (CVVHF) and continuous venovenous hemodiafiltration (CVVHDF) in 4 heart transplant recipients treated for at least 6 days with mycophenolate mofetil (MMF) in addition to cyclosporine and corticosteroids. The sieving coefficient ranged from 0.02 to 0.04 for MPA and from 0.15 to 0.33 for MPAG. The clearance of MPAG by CVVHDF or CVVHF ranged from 7.52 mL/min to 19.45 mL/min, and that of MPA was lower than 2.28 mL/min, with no significant difference between the two continuous replacement therapies. Whereas MPA percentage recovered by hour following CVVHDF or CVVHF was negligible, the percentage of MPAG represents up to 12.9% of the administered dose. A relevant decrease in the free fraction of MPA and MPAG was observed after continuous renal replacement therapy (CRRT). These preliminary results demonstrate that MPAG is able to permeate the filter. In light of the alteration in protein binding following CRRT and the competition between MPA and MPAG to albumin site, drug monitoring of MPA and MPAG in patients undergoing CVVHDF or CVVHF may be suggested. Moreover, monitoring of free MPA may be of interest for these patients.

From the *Université de Lyon, Université Lyon 1, ISPB, Département de Pharmacie Clinique, de Pharmacocinétique et d'Evaluation du Médicament, Lyon; and †Laboratoire de Pharmacocinétique Clinique and ‡Pôle Médico-chirurgical de Transplantation Cardiaque Adulte, Hospices Civils de Lyon, Hôpital Cardio-vasculaire et Pneumologique Louis Pradel, Bron, France.

Received for publication August 29, 2007; accepted November 15, 2007.

Correspondence: Prof. Roselyne Boulieu, PhD, Université Lyon 1, ISPB, Département de Pharmacie Clinique, de Pharmacocinétique et d'Evaluation du Médicament, 8 avenue Rockefeller, Lyon F-69373, France (e-mail: roselyne.boulieu@sante.univ-lyon1.fr).

© 2008 Lippincott Williams & Wilkins, Inc.